Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.
9hon MSN
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...
Changes to vaccine recommendations under Health Secretary Robert F. Kennedy Jr. are confusing professionals in the pharmaceutical and insurance industries.
Through an exclusive partnership with Eli Lilly, the company has begun distributing and promoting Yurpeak (Tirzepatide) in ...
Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback